{"type":"trials","record":{"id":87099,"source_id":"isrctn","external_id":"ISRCTN18639700","title":"Dark adaptation and Retinal Topography in AMD (DART-AMD)","brief_summary":"Delayed dark adaptation is widely reported to be a feature of intermediate age-related macular degeneration (iAMD). However, the extent of the deficit varies substantially between individuals. One explanation for this might be the variability between individuals in the topographical distribution of structural features of AMD. Typically, rates of dark adaptation are measured at a single retinal locus. If this happens to coincide with a localised region of structural abnormality in a particular individual, this may result in an increased delay in dark adaptation. The technology has not previously been available to investigate this hypothesis, but the development of software which enables fundus-controlled microperimetry to be used to evaluate rates of adaptation at specific and customised retinal loci makes this a viable topic of investigation.","overall_status":"Recruiting","phases":[],"study_type":"Observational","sponsor":"City, University of London","enrollment":72,"countries":["United Kingdom","England"],"start_date":"2025-04-01","completion_date":"2027-12-31","last_update_date":"2025-04-01","source_url":"https://www.isrctn.com/ISRCTN18639700","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T03:46:39.792962+00:00","last_seen_at":"2026-09-25T03:46:39.551+00:00","metadata":{"sex":"All","age_range":"Senior","comparator":null,"attribution":"Source: ISRCTN ISRCTN18639700; retrieved 2026-09-25","interventions":["Other"],"reuse_license":"Registry contribution CC BY 4.0; generated metadata CC0","registry_source":"ISRCTN","outcome_measures":["The rate of the second component of rod-mediated dark adaptation (compared between feature-bearing and non-feature-bear…","1. The time constant of cone-mediated dark adaptation. This will be measured at baseline (again within 2 weeks for thos…"],"design_description":"Observational","source_has_results":false},"controlled_terms":["Age-related macular degeneration","The cross-sectional component involves 72 individuals with iAMD. The scotopic MAIA (sMAIA) microperimeter will be contr…","Other"],"relevance_confidence":100,"source_quality_score":98,"freshness_score":65,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T03:46:42.633202+00:00","duplicate_cluster_key":"id:isrctn18639700","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2025-04-01 to 2027-12-31","comparator":null,"confidence":"structured-source","population":"All · Senior","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T03:46:39.556Z","intervention":["Other"],"participants":72,"study_design":"Observational","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["The rate of the second component of rod-mediated dark adaptation (compared between feature-bearing and non-feature-bear…","1. The time constant of cone-mediated dark adaptation. This will be measured at baseline (again within 2 weeks for thos…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as Observational."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ISRCTN Registry","homepage_url":"https://www.isrctn.com/"}},"canonical_url":"https://www.immortal.life/trials/87099","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}